Treatments & Therapies

Key Takeaways from AAIC 2025: Lifestyle Modifications, Biomarkers, Amyloid-Targeting Therapies, and More

Ana C. Pereira, MD

Podcast

Beyond Slowing Cognitive Decline: Patient and Caregiver Perspectives on Alzheimer’s Treatment

Catherine Auriemma, MD, MSHP, and Carolyn Chow, MD

Podcast

Blarcamesine: An Investigational Oral Drug for Alzheimer Disease

Timo Grimmer, MD

Podcast

The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

Gary E. Gibson, PhD

Podcast

Results of the Clarity AD Trial Assessing Lecanemab Treatment for Early Alzheimer Disease

Lynn D. Kramer, MD, FAAN and Christopher van Dyck, MD

Podcast

Labcorp's Biomarker Testing for Alzheimer Disease

Joseph M. Volpe, PhD

Podcast

Current Evidence of Lifestyle Factors to Mitigate Cognitive Decline

Resource

Significant Milestones in Alzheimer Disease Diagnosis and Treatment

Resource

Emerging Therapeutic Targets for Alzheimer Disease

Howard Fillit, MD

Podcast

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company

Podcast

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company

Podcast